Carboplatin is an important alkylating agent clinically used to treat several types of cancers including ovarian carcinoma (OC). However, drug resistance is a frequent obstacle for successful treatment. In the quest for new (metallo)drugs to treat OC with acquired resistance, the use of silver‑based compounds was recently proposed with silver(I)–N–heterocyclic carbene containing ligands that showed high potential towards cisplatin-resistant OC cell lines[1, 2]. In this frame, we are exploring the synthesis and anticancer properties of novel silver(I) compounds containing 2,2’-bipyridine derivatives and triphenylphosphane (PPh₃) or 1,2-bis(diphenylphosphino)ethane (dppe) co-ligands. All compounds were fully characterized using several spectroscopic techniques (NMR, UV–Vis, ESI–MS, and FTIR) and single crystal X-ray diffraction. Their cytotoxic activity was tested in two human OC models (SKOV-3 and MESOV), their carboplatin-resistant counterparts and non-malignant fibroblasts F331. In order to evaluate the impact of P53, also HCT116 colon carcinoma cells in comparison to their isogenic P53-knockout clone (HCT116/p53ko) were tested. In SKOV-3 and F331, all compounds had a rather weak cytotoxicity with IC50 values in the low µM range. In contrast, the MESOV and HCT116 cells were characterized by a high sensitivity to the dppe-Ag(I) drugs already at low nM concentrations. In addition, they were not affected by drug resistance to carboplatin or by P53. This indicates that the dppe-Ag(I) compounds have a high tumor selectivity for special cancer types, which makes them interesting drug candidates against drug-resistant OC.